<DOC>
	<DOCNO>NCT01295632</DOCNO>
	<brief_summary>This two part study drug MK-8669 ( ridaforolimus ) give MK-2206 MK-0752 . In Part A study , preliminary maximum tolerate dose ( MTD ) drug combination find give sequentially high dos study drug . An expansion cohort participant may enrol confirm MTD . New cohort dose level may enrol , depend rate dose limit toxicity ( DLTs ) plan cohort . In Part B , assessment efficacy drug combination select advanced cancer make recommend dose use Phase 2 study ( RPTD ) find . As 19 July 2012 MK-0752 arm study fully enrol closed recruitment . As 30 November 2012 , additional participant prostate cancer enrol .</brief_summary>
	<brief_title>Safety Tolerability Different Dose Combinations Ridaforolimus With MK-2206 MK-0752 Participants With Advanced Cancer ( MK-8669-049 )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Part A Study : Participant must histologicallyconfirmed metastatic locally advanced solid tumor fail respond standard therapy , progress despite standard therapy , standard therapy exist . Non Hodgkin Lymphoma ( NHL ) participant ( Part A ) , must histologically confirm relapsed/refractory NHL . There limit number prior treatment regimen . Part B Study : Participant must performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Participant must adequate organ function . Participants must willing use effective method contraception . Participant able swallow capsule surgical anatomical condition preclude participant swallow absorb oral medication ongoing basis . Participant history prior malignancy exception cervical intraepithelial neoplasia ; basal cell carcinoma skin ; adequately treat localized prostate carcinoma ProstateSpecific Antigen ( PSA ) &lt; 1.0 ; undergone potentially curative therapy evidence disease five year , deem low risk recurrence his/her treat physician . Participant least one measurable recurrent metastatic lesion ( solitary lesion , histological/cytological confirmation neoplastic nature require ) exception prostate cancer participant require measurable disease participant PSA level &gt; 10 ng/mL . Participant must agree provide archival newlyobtained tumor tissue sample . Ridaforolimus + MK2206 Treatment Arm : Participant must histologicallyconfirmed prostate cancer refractory hormone therapy participant receive number prior treatment regimen ( long recruit 30 November 2012 ) , OR Participant must histologicallyconfirmed breast cancer participant receive number prior treatment regimen . Archival fresh tissue must demonstrate low RASgene signature high Ki67 index label estrogen receptor ( ER ) + Ridaforolimus + MK0752 Treatment Arm : Participant must histologicallyconfirmed recurrent ( either primary secondary ) glioblastoma multiforme radiographic evidence progression/recurrence disease , 2 prior treatment regimens recurrent disease , prior treatment bevacizumab , OR Participants must histologicallyconfirmed relapsed refractory ovarian cancer participant receive 2 prior treatment regiment either relapse refractory first line treatment . Participant chemotherapy radiotherapy within 4 week prior study Day 1 ( 6 week nitrosoureas , mitomycin C ) , biological therapy ( exclude antibody ) within 2 week prior study Day 1 , recover ( ≤Grade 1 baseline ) adverse event due agent administer 4 week earlier . Luteinizinghormone release hormone ( LHRH ) use prostate cancer patient permit ; participant prostate cancer previously treat flutamide nilutamide require 4 week washout period participant previously treat bicalutamide require 6 week washout period study drug administration . Participant currently participate participate study investigational compound device within 28 day , 5X halflife investigational compound ( include monoclonal antibody ) , whichever longer , Day 1 study . Participants know symptomatic progress Central Nervous System ( CNS ) metastases and/or carcinomatous meningitis exclude . However , participant CNS metastases asymptomatic complete course therapy eligible study provide clinically stable 1 month prior entry define : ( 1 ) evidence new enlarge CNS metastasis ( 2 ) steroid stable dose steroid . Participant known hypersensitivity component study drug analog . Participant prior exposure agent target study drug . Participant significant uncontrolled cardiovascular disease , include New York Heart Association ( NYHA ) Class IIIIV heart failure , unstable angina , myocardial infarction within last 6 month . Participant know diabetic participant poorly control screening . Participant know psychiatric substance abuse disorder would interfere compliance study requirement . Participant , time signing informed consent , regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) drug alcohol abuse . Participant pregnant breastfeeding , expect conceive father child within project duration study . Participant known Human Immunodeficiency Virus ( HIV ) positive . Participant active Hepatitis B C. Participant symptomatic ascites pleural effusion . A participant clinically stable follow treatment condition eligible . Participant requirement concurrent treatment immunosuppressive agent prescribed corticosteroid stable dos ≥ 2 week prior first plan dose study drug . Participant requirement concurrent treatment medication ( ) strongly moderate induce inhibit cytochrome P450 ( CYP3A ) . Participants medication ≥ 2 week prior first dose study medication . For participant glioblastoma , dexamethasone discontinue least 1 week prior first dose study drug . For participant Ridaforolimus + MK0752 treatment arm : Participant require anticipated require concomitant therapy enzymeinducing antiepileptic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Recurrent glioblastoma multiforme</keyword>
	<keyword>Hormone resistant prostate cancer</keyword>
	<keyword>Relapsed ovarian carcinoma</keyword>
	<keyword>Refractory ovarian carcinoma</keyword>
	<keyword>Refractory breast cancer</keyword>
	<keyword>Relapsed breast cancer</keyword>
</DOC>